Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 7,055,000 | -8,933,000 | 8,040,000 | 6,345,000 | 7,014,000 |
| Depreciation Amortization | 4,011,000 | 9,600,000 | 9,760,000 | 10,276,000 | 10,686,000 |
| Income taxes - deferred | -965,000 | -2,089,000 | -3,288,000 | -2,738,000 | -1,393,000 |
| Accounts receivable | -295,000 | 264,000 | -995,000 | -663,000 | -1,054,000 |
| Other Working Capital | -455,000 | 810,000 | -1,914,000 | -2,229,000 | -1,261,000 |
| Other Operating Activity | 4,805,000 | 15,538,000 | 2,257,000 | 2,075,000 | 2,215,000 |
| Operating Cash Flow | $14,156,000 | $15,190,000 | $13,860,000 | $13,066,000 | $16,207,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -25,000 | 353,000 | -1,041,000 | 2,819,000 | -1,282,000 |
| PPE Investments | -1,311,000 | -1,248,000 | -1,209,000 | -1,118,000 | -973,000 |
| Net Acquisitions | -2,873,000 | -20,722,000 | -260,000 | -2,981,000 | -862,000 |
| Sale Of Investment | 77,000 | 265,000 | 215,000 | 218,000 | 2,579,000 |
| Investing Cash Flow | $-4,132,000 | $-21,352,000 | $-2,295,000 | $-1,062,000 | $-538,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 25,000 | 3,086,000 | -120,000 | 194,000 | -160,000 |
| Debt Issued | 5,740,000 | 12,883,000 | 4,455,000 | 5,926,000 | 0 |
| Debt Repayment | -10,940,000 | -2,873,000 | -3,879,000 | -11,431,000 | -6,022,000 |
| Common Stock Repurchased | 0 | 0 | -5,155,000 | -8,001,000 | -6,287,000 |
| Dividend Paid | -5,045,000 | -4,863,000 | -4,744,000 | -4,634,000 | -4,396,000 |
| Other Financing Activity | -128,000 | -3,106,000 | 27,000 | 984,000 | 641,000 |
| Financing Cash Flow | $-10,348,000 | $5,127,000 | $-9,416,000 | $-16,962,000 | $-16,224,000 |
| Exchange Rate Effect | 195,000 | -137,000 | 45,000 | -33,000 | -102,000 |
| Beginning Cash Position | 10,347,000 | 11,519,000 | 9,325,000 | 14,316,000 | 14,973,000 |
| End Cash Position | 10,218,000 | 10,347,000 | 11,519,000 | 9,325,000 | 14,316,000 |
| Net Cash Flow | $-129,000 | $-1,172,000 | $2,194,000 | $-4,991,000 | $-657,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 14,156,000 | 15,190,000 | 13,860,000 | 13,066,000 | 16,207,000 |
| Capital Expenditure | -1,311,000 | -1,248,000 | -1,209,000 | -1,118,000 | -973,000 |
| Free Cash Flow | 12,845,000 | 13,942,000 | 12,651,000 | 11,948,000 | 15,234,000 |